Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(7): e102264, 2014.
Article in English | MEDLINE | ID: mdl-25033204

ABSTRACT

AIM: Argininosuccinate synthetase (ASS) is essential for recycling L-citrulline, the by-product of NO synthase (NOS), to the NOS substrate L-arginine. Here, we assessed whether disturbed arginine resynthesis modulates endothelium-dependent vasodilatation in normal and diabetic male mice. METHODS AND RESULTS: Endothelium-selective Ass-deficient mice (Assfl/fl/Tie2Cretg/- = Ass-KOTie2) were generated by crossing Assfl/fl mice ( = control) with Tie2Cre mice. Gene ablation in endothelial cells was confirmed by immunohistochemistry. Blood pressure (MAP) was recorded in 34-week-old male mice. Vasomotor responses were studied in isolated saphenous arteries of 12- and 34-week-old Ass-KOTie2 and control animals. At the age of 10 weeks, diabetes was induced in control and Ass-KOTie2 mice by streptozotocin injections. Vasomotor responses of diabetic animals were studied 10 weeks later. MAP was similar in control and Ass-KOTie2 mice. Depletion of circulating L-arginine by arginase 1 infusion or inhibition of NOS activity with L-NAME resulted in an increased MAP (10 and 30 mmHg, respectively) in control and Ass-KOTie2 mice. Optimal arterial diameter, contractile responses to phenylephrine, and relaxing responses to acetylcholine and sodium nitroprusside were similar in healthy control and Ass-KOTie2 mice. However, in diabetic Ass-KOTie2 mice, relaxation responses to acetylcholine and endothelium-derived NO (EDNO) were significantly reduced when compared to diabetic control mice. CONCLUSIONS: Absence of endothelial citrulline recycling to arginine did not affect blood pressure and systemic arterial vasomotor responses in healthy mice. EDNO-mediated vasodilatation was significantly more impaired in diabetic Ass-KOTie2 than in control mice demonstrating that endothelial arginine recycling becomes a limiting endothelial function in diabetes.


Subject(s)
Arginine/biosynthesis , Argininosuccinate Synthase/genetics , Blood Pressure/physiology , Diabetes Mellitus, Experimental/metabolism , Heart Rate/physiology , Acetylcholine/pharmacology , Animals , Arginase/metabolism , Arginine/blood , Blood Pressure/genetics , Citrulline/blood , Citrulline/metabolism , Diabetes Mellitus, Experimental/genetics , Endothelial Cells/cytology , Endothelial Cells/enzymology , Endothelium/cytology , Endothelium/enzymology , Endothelium/metabolism , Female , Heart Rate/genetics , Male , Mice , Mice, Knockout , Muscle, Smooth, Vascular/physiology , NG-Nitroarginine Methyl Ester , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Nitroprusside/pharmacology , Phenylephrine/pharmacology , Vasoconstrictor Agents/pharmacology , Vasodilation/genetics , Vasodilation/physiology , Vasodilator Agents/pharmacology , Vasomotor System/metabolism
2.
J Hypertens ; 30(9): 1799-808, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22828083

ABSTRACT

BACKGROUND: Endothelin-1 (ET1) is a potent vasoconstrictor peptide with pro-mitogenic and pro-inflammatory properties and is therefore of interest in the development of endothelial dysfunction, endothelium-dependent flow-related remodeling, and hypertension-related remodeling. ET1 can be formed through cleavage of big ET1 by endothelin-converting enzyme (ECE) and neutral endopeptidase (NEP). METHOD: We investigated whether the dual NEP/ECE inhibitor SOL1 improves resistance artery function and structure in 12 weeks old spontaneously hypertensive rats (SHRs) and whether arterial structural responses to decreased (-90%) or increased (+100%) blood flow are impaired in young SHRs. To this end two groups of SHRs received chronic 4-week treatment at two different time points (4-8 and 8-12 weeks) prior to the experiment. We compared in-vitro effects of cyclo-oxygenase inhibition (1 µmol/l indomethacine), nitric oxide synthase inhibition (100 µmol/l N(ω)-L-nitro arginine methyl ester), and stimulation of the endothelium by 0.001-10 µmol/l acetylcholine (ACh) in isolated third-order mesenteric arteries of SHRs and aged-matched Wistar-Kyoto (WKY) rats. RESULTS: SOL1 had no effect on blood pressure in SHRs or WKY rats. ACh caused biphasic effects in mesenteric arteries of SHRs. The contractile component (endothelium-derived contractile factor) was absent in WKY and abolished by acute indomethacin administration or chronic SOL1 treatment. Endothelium-derived nitric oxide-type responses did not differ in both strains and were not influenced by SOL1 treatment. Endothelium-derived hyperpolarizing factor-type responses were severely impaired in SHRs as compared to WKY rats and were normalized by chronic SOL1 treatment. In first-order mesenteric arteries, outward flow-induced remodeling was impaired in SHRs. Chronic SOL1 treatment did not restore this response. CONCLUSION: Thus chronic SOL1 treatment during the development of hypertension in SHRs has no effect on blood pressure but improves several aspects of endothelium-dependent vasomotor responses but not arterial remodeling.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Endothelium, Vascular/physiology , Mesenteric Arteries/physiopathology , Peptide Hydrolases/drug effects , Protease Inhibitors/pharmacology , Animals , Hypertension/enzymology , Hypertension/physiopathology , Rats , Rats, Inbred SHR , Rats, Inbred WKY
3.
Hypertens Res ; 35(11): 1093-101, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22786567

ABSTRACT

Arteries from young healthy animals respond to chronic changes in blood flow and blood pressure by structural remodeling. We tested whether the ability to respond to decreased (-90%) or increased (+100%) blood flow is impaired during the development of deoxycorticosterone acetate (DOCA)-salt hypertension in rats, a model for an upregulated endothelin-1 system. Mesenteric small arteries (MrA) were exposed to low blood flow (LF) or high blood flow (HF) for 4 or 7 weeks. The bioavailability of vasoactive peptides was modified by chronic treatment of the rats with the dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor SOL1. After 3 or 6 weeks of hypertension, the MrA showed hypertrophic arterial remodeling (3 weeks: media cross-sectional area (mCSA): 10±1 × 10(3) to 17±2 × 10(3) µm(2); 6 weeks: 13±2 × 10(3) to 24±3 × 10(3) µm(2)). After 3, but not 6, weeks of hypertension, the arterial diameter was increased (Ø: 385±13 to 463±14 µm). SOL1 reduced hypertrophy after 3 weeks of hypertension (mCSA: 6 × 10(3)±1 × 10(3) µm(2)). The diameter of the HF arteries of normotensive rats increased (Ø: 463±22 µm) but no expansion occurred in the HF arteries of hypertensive rats (Ø: 471±16 µm). MrA from SOL1-treated hypertensive rats did show a significant diameter increase (Ø: 419±13 to 475±16 µm). Arteries exposed to LF showed inward remodeling in normotensive and hypertensive rats (mean Ø between 235 and 290 µm), and infiltration of monocyte/macrophages. SOL1 treatment did not affect the arterial diameter of LF arteries but reduced the infiltration of monocyte/macrophages. We show for the first time that flow-induced remodeling is impaired during the development of DOCA-salt hypertension and that this can be prevented by chronic NEP/ECE inhibition.


Subject(s)
Blood Pressure/physiology , Desoxycorticosterone/adverse effects , Hypertension/pathology , Hypertension/physiopathology , Mesenteric Arteries/pathology , Mesenteric Arteries/physiopathology , Regional Blood Flow/physiology , Animals , Aspartic Acid Endopeptidases/antagonists & inhibitors , Aspartic Acid Endopeptidases/drug effects , Benzazepines/pharmacology , Blood Pressure/drug effects , Cell Movement/drug effects , Cell Movement/physiology , Disease Models, Animal , Endothelin-Converting Enzymes , Enzyme Inhibitors/pharmacology , Hypertension/chemically induced , Hypertrophy/chemically induced , Macrophages/pathology , Metalloendopeptidases/antagonists & inhibitors , Metalloendopeptidases/drug effects , Monocytes/pathology , Neprilysin/antagonists & inhibitors , Neprilysin/drug effects , Rats , Rats, Wistar , Regional Blood Flow/drug effects , Vascular Resistance/drug effects , Vascular Resistance/physiology
4.
Swiss Med Wkly ; 142: w13553, 2012.
Article in English | MEDLINE | ID: mdl-22481247

ABSTRACT

Atherosclerosis, a progressive disease of medium- and large-sized arteries, constitutes the major cause of death in developed countries, and is becoming increasingly prevalent in developing countries as well. The main consequences of atherosclerosis are myocardial infarction, cerebral infarction and aortic aneurysm. This inflammatory disease is characterised by specific intimal lesions where lipids, leukocytes and smooth muscle cells accumulate in the arterial wall over time. Risk factors for atherosclerosis can mainly be divided into two groups: i) risk factors induced by environment and behaviour (e.g., Western diet, smoking and sedentary lifestyle) and ii) genetic risk factors. Multiple epidemiological studies have associated a single nucleotide polymorphism (SNP) in the GJA4 gene, coding for connexin37 (Cx37), with increased risk for atherosclerosis and myocardial infarction. Connexins form gap junctions or hemi-channels that mediate an exchange of factors between i) the cytosol of two adjacent cells or ii) the cytosol and the extracellular environment, respectively. The GJA4 SNP codes for a proline-to-serine substitution at amino acid 319 in the regulatory C-terminus of the Cx37 protein, thereby altering basic and regulatory properties of its gap junction- and hemi-channels. In this review we discuss current evidence for mechanisms that link the GJA4 SNP to atherosclerosis or thrombus formation after plaque rupture.


Subject(s)
Atherosclerosis/genetics , Connexins/genetics , Thrombosis/genetics , Atherosclerosis/metabolism , Blood Platelets/metabolism , Connexins/metabolism , Gap Junctions/genetics , Gap Junctions/metabolism , Humans , Polymorphism, Single Nucleotide , Thrombosis/metabolism , Gap Junction alpha-4 Protein
5.
PLoS One ; 6(12): e29222, 2011.
Article in English | MEDLINE | ID: mdl-22195025

ABSTRACT

BACKGROUND: We have previously shown that essential hypertension in humans and spontaneously hypertensive rats (SHR), is associated with increased levels of ceramide and marked alterations in sphingolipid biology. Pharmacological elevation of ceramide in isolated carotid arteries of SHR leads to vasoconstriction via a calcium-independent phospholipase A(2), cyclooxygenase-1 and thromboxane synthase-dependent release of thromboxane A(2). This phenomenon is almost absent in vessels from normotensive Wistar Kyoto (WKY) rats. Here we investigated whether lowering of blood pressure can reverse elevated ceramide levels and reduce ceramide-mediated contractions in SHR. METHODS AND FINDINGS: For this purpose SHR were treated for 4 weeks with the angiotensin II type 1 receptor antagonist losartan or the vasodilator hydralazine. Both drugs decreased blood pressure equally (SBP untreated SHR: 191±7 mmHg, losartan: 125±5 mmHg and hydralazine: 113±14 mmHg). The blood pressure lowering was associated with a 20-25% reduction in vascular ceramide levels and improved endothelial function of isolated carotid arteries in both groups. Interestingly, losartan, but not hydralazine treatment, markedly reduced sphingomyelinase-induced contractions. While both drugs lowered cyclooxygenase-1 expression, only losartan and not hydralazine, reduced the endothelial expression of calcium-independent phospholipase A(2). The latter finding may explain the effect of losartan treatment on sphingomyelinase-induced vascular contraction. CONCLUSION: In summary, this study corroborates the importance of sphingolipid biology in blood pressure control and specifically shows that blood pressure lowering reduces vascular ceramide levels in SHR and that losartan treatment, but not blood pressure lowering per se, reduces ceramide-mediated arterial contractions.


Subject(s)
Antihypertensive Agents/pharmacology , Blood Vessels/drug effects , Blood Vessels/metabolism , Hydralazine/pharmacology , Losartan/pharmacology , Sphingolipids/metabolism , Animals , Blood Pressure/drug effects , Blood Vessels/physiopathology , Carotid Arteries/drug effects , Carotid Arteries/pathology , Carotid Arteries/physiopathology , Ceramides/blood , Endothelium, Vascular/drug effects , Endothelium, Vascular/enzymology , Endothelium, Vascular/physiopathology , Group VI Phospholipases A2/metabolism , In Vitro Techniques , Male , Rats , Rats, Inbred SHR , Sphingomyelin Phosphodiesterase/metabolism , Vasoconstriction/drug effects
6.
Hypertension ; 58(1): 99-106, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21606388

ABSTRACT

Slow dissociation of endothelin 1 from its endothelin A receptors is responsible for the long-lasting vasoconstrictor effects of the peptide. We showed recently that calcitonin gene-related peptide selectively terminates long-lasting contractile responses to endothelin 1 in isolated rat mesenteric arteries. Here we assessed whether the antiendothelinergic effect of calcitonin gene-related peptide is vascular bed specific and may terminate long-lasting pressor responses to exogenous and locally produced endothelin 1 in vivo. Regional heterogeneity of the calcitonin gene-related peptide/endothelin A receptor cross-talk was explored in arteries isolated from various rat organs. Endothelin A receptor-mediated arterial contractions were terminated by calcitonin gene-related peptide in rat mesenteric, renal, and spermatic arteries but not in basilar, coronary, epigastric, gastric, splenic, and saphenous arteries. Endothelin A receptor antagonism only ended endothelin 1-induced contractions in spermatic arteries. In anesthetized rats, instrumented with Doppler flow probes to record regional blood flows, long-lasting pressor and vasoconstrictor responses to an intravenous bolus injection of endothelin 1 or big endothelin 1 were transiently reduced by sodium nitroprusside (NO donor) but terminated by intravenously administered calcitonin gene-related peptide. In conscious rats, calcitonin gene-related peptide but not sodium nitroprusside terminated prolonged (>60-minute) pressor responses to endothelin 1 but not those to intravenous infusion of phenylephrine. In conclusion, pressor responses to circulating and locally produced endothelin 1 that are resistant to endothelin receptor antagonism and NO can be terminated by a regionally selective effect of calcitonin gene-related peptide. Calcitonin gene related peptide receptor agonism may represent a novel strategy to treat endothelin 1-associated cardiovascular pathologies.


Subject(s)
Arteries/physiopathology , Calcitonin Gene-Related Peptide/pharmacology , Endothelin-1/pharmacology , Hypertension/physiopathology , Regional Blood Flow/drug effects , Vasoconstriction/drug effects , Animals , Arteries/drug effects , Blood Pressure/drug effects , Disease Models, Animal , Male , Rats , Rats, Inbred WKY , Vasodilator Agents/pharmacology
7.
Trends Pharmacol Sci ; 32(6): 345-51, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21481481

ABSTRACT

The paracrine signaling peptide endothelin-1 (ET1) is involved in cardiovascular diseases, cancer and chronic pain. It acts on class A G-protein-coupled receptors (GPCRs) but displays atypical pharmacology. It binds tightly to ET receptor type A (ET(A)) and causes long-lasting effects. In resistance arteries, the long-lasting contractile effects can only be partly and reversibly relaxed by low-molecular-weight ET(A) antagonists (ERAs). However, the neuropeptide calcitonin-gene-related peptide selectively terminates binding of ET1 to ET(A). We propose that ET1 binds polyvalently to ET(A) and that ERAs and the physiological antagonist allosterically reduce ET(A) functions. Combining the two-state model and the two-domain model of GPCR function and considering receptor activation beyond agonist binding might lead to better anti-endothelinergic drugs. Future studies could lead to compounds that discriminate between ET(A)-mediated effects of the endogenous isopeptides ET1, ET2 and ET3 and that become more effective when the activity of the endogenous endothelin system is elevated.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Endothelins/metabolism , Pain/physiopathology , Receptor, Endothelin A , Vasodilator Agents/metabolism , Allosteric Regulation , Animals , Cardiovascular Diseases/physiopathology , Chronic Disease , Endothelin A Receptor Antagonists , Humans , Models, Biological , Neoplasms/physiopathology , Protein Binding/physiology , Rats , Receptor, Endothelin A/agonists , Receptor, Endothelin A/metabolism , Structure-Activity Relationship
8.
PLoS One ; 5(6): e10917, 2010 Jun 01.
Article in English | MEDLINE | ID: mdl-20532232

ABSTRACT

BACKGROUND: Endothelin-1 (ET-1), a long-acting paracrine mediator, is implicated in cardiovascular diseases but clinical trials with ET-receptor antagonists were not successful in some areas. We tested whether the quasi-irreversible receptor-binding of ET-1 (i) limits reversing effects of the antagonists and (ii) can be selectively dissociated by an endogenous counterbalancing mechanism. METHODOLOGY/PRINCIPAL FINDINGS: In isolated rat mesenteric resistance arteries, ET(A)-antagonists, endothelium-derived relaxing factors and synthetic vasodilators transiently reduced contractile effects of ET-1 but did not prevent persistent effects of the peptide. Stimuli of peri-vascular vasodilator sensory-motor nerves such as capsaicin not only reduced but also terminated long-lasting effects of ET-1. This was prevented by CGRP-receptor antagonists and was mimicked by exogenous calcitonin gene-related peptide (CGRP). Using 2-photon laser scanning microscopy in vital intact arteries, capsaicin and CGRP, but not ET(A)-antagonism, were observed to promote dissociation of pre-existing ET-1/ET(A)-receptor complexes. CONCLUSIONS: Irreversible binding and activation of ET(A)-receptors by ET-1 (i) occur at an antagonist-insensitive site of the receptor and (ii) are selectively terminated by endogenously released CGRP. Hence, natural stimuli of sensory-motor nerves that stimulate release of endogenous CGRP can be considered for therapy of diseases involving ET-1.


Subject(s)
Arteries/drug effects , Calcitonin Gene-Related Peptide/pharmacology , Endothelin-1/pharmacology , Receptor, Endothelin A/metabolism , Sensory Receptor Cells/drug effects , Animals , Arteries/physiology , Protein Binding , Rats
9.
J Pharmacol Exp Ther ; 331(1): 87-95, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19628632

ABSTRACT

We tested the hypothesis that endothelin-1 (ET-1) modulates sensory-motor nervous arterial relaxation by prejunctional and postjunctional mechanisms. Isolated rat mesenteric resistance arteries were investigated with immunohistochemistry, wire-myography, and pharmacological tools. ET(A)- and ET(B)-receptors could be visualized on the endothelium and smooth muscle and on periarterial fibers containing calcitonin gene-related peptide (CGRP). Arterial contractile responses to ET-1 (0.25-16 nM) were not modified by blockade of ET(B)-receptors, NO-synthase, and cyclooxygenase or desensitization of transient receptor potential cation channel, subfamily V, member 1 (TRPV1) with capsaicin. ET-1 reversed relaxing responses to CGRP in depolarized arteries. This effect was inhibited by ET(A)-antagonists. It was not selective because ET-1 also reversed relaxing responses to Na-nitroprusside (SNP) and because phenylephrine (PHE; 0.25-16 microM) similarly reversed relaxing responses to CGRP or SNP. Conversely, contractile responses to ET-1 were, compared with PHE, hypersensitive to the relaxing effects of the TRPV1-agonist capsaicin and to exogenous CGRP, but not to acetylcholine, forskolin, pinacidil, or SNP. In conclusion, ET-1 does not stimulate sensory-motor nervous arterial relaxation, but ET(A)-mediated arterial contractions are selectively sensitive to relaxation by the sensory neurotransmitter CGRP. This does not involve NO, cAMP, or ATP-sensitive K(+) channels.


Subject(s)
Calcitonin Gene-Related Peptide/physiology , Endothelin-1/physiology , Mesenteric Arteries/physiology , Muscle Contraction/physiology , Muscle Relaxation/physiology , Vascular Resistance/physiology , Vasodilation/physiology , Animals , Endothelin A Receptor Antagonists , Endothelin B Receptor Antagonists , Endothelin-1/antagonists & inhibitors , Male , Muscle, Smooth, Vascular/physiology , Rats , Rats, Sprague-Dawley , Receptor, Endothelin A/physiology , Receptor, Endothelin B/physiology , Vasoconstriction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...